

# GRIFOLS

## Grifols awarded prestigious LEED Gold certification for new building at HQ complex

- *U.S. Green Building Council recognizes sustainable design and construction that will enable energy savings of up to 32% while reducing water consumption 42%*
- *Grifols also has multiple buildings at its manufacturing site in Clayton, N.C. (U.S.), that have received either LEED or Green Globes certification*
- *Recognized as one of the world's most sustainable companies, Grifols reinforces the environmental pillar of its sustainability strategy and continues to advance on its roadmap*

**Barcelona, Spain, July 11, 2022** - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines with a proven track record of more than 110 years contributing to people's health and well-being, today announced it has received the LEED Gold certification for a new building at its headquarters in Sant Cugat del Vallès (Barcelona).

The LEED (Leadership in Energy and Environmental Design) rating system, developed and conferred by the U.S. Green Building Council (USGBC), is the most widely used green building rating system in the world.

Grifols received its certification for a sustainable design and construction that prioritizes water and energy conservation, minimization of greenhouse gases, the use of environmentally friendly materials as well as indoor safety and environmental quality.

The new luminous 12,542 square-meter, five-story building employs advanced technologies that will lead to energy savings of nearly a third compared with standard constructions. Rooftop photovoltaic panels supply part of the 100% renewables-based electricity consumption. Expected water usage will be 42% less thanks to highly efficient systems as well as the storage and use of rainwater for irrigation including the maintenance of a 'Green Roof' that sits atop the auditorium and insulates it from the exterior with indigenous vegetation.

The auditorium itself, which seats 379 and provides full access for people with disabilities, is equipped with a cinema-quality LED screen measuring 11 meters-wide. Simultaneous translation capabilities facilitate global meetings.

"Grifols delivers on its commitments and continues to work for a more sustainable and livable planet," said Daniel Fleta, Grifols Chief Industrial Officer. "We're proud of the LEED Gold certification for our new building, another example of Grifols' ongoing efforts to incorporate respectful and sustainable practices in everything we do."

# GRIFOLS

With this commendation, Grifols, recognized as one of the most sustainable companies in the world, reinforces the environmental pillar of its sustainability strategy and continues to advance on its roadmap.

The company's manufacturing site in Clayton, N.C. (U.S.), has multiple buildings that have received either LEED certification or Green Globes designation from the Green Building Initiative, which evaluates an industrial building's energy and water use, emissions and project management. The Clayton site's environmental practices have enabled it to continually renew its UL-awarded Zero Waste to Landfill Gold Certification.

Aligned with the United Nations 2030 Agenda for Sustainable Development, Grifols has developed its own goals to be completed by the end of the decade that feature 30 ambitious, concrete and measurable commitments that include reducing energy consumption and greenhouse emissions, increasing energy use from renewable sources, applying circular economy measures and protecting biodiversity. Grifols is striving to reach net zero emissions by 2050.

Other sustainability goals address areas including gender equality, talent development, social initiatives, product donations and a more sustainable supply chain, among others.

All of the company's sustainability information is public and available at [Grifols | Sustainability](#).

## Media Contact:

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 and committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 110 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare and chronic conditions that can be life-threatening. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

# GRIFOLS

Grifols, with more than 23,000 employees in more than 30 countries and region, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)



## LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.